Endovia Health Sciences Inc
EDVAHealthcare·Biotechnology·USA·Nano·AMEX·Nov 12 • 3:36 PM ET
0.17-0.01 (-4.02%)
2026-11-12 21:42 CET
Market cap
$1.91M
Revenue, TTM
0.00 USD m
Net income, TTM
-2.05 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-0.67
Price
EDVA against its 20, 50 and 200-day averagesPatternshover a marker to name it
EPS mean, own scale
97.5% under the 52-week high of 6.76 on 2 Dec 2025. 52-week low 0.13 on 15 Oct 2026. Last 15 sessions, 29.3% high to low. This session is unfinished.
Volume 0.15× normal · the line is the 50-bar volume average
Setup. RS line 0
CANSLIM 2 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50% — not on the tape: EPS Growth This Year: High (>25%)
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 1 of 4 — not on the tape: EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 0 of 5 — fails: Net Profit Margin: High (>20%); Current Ratio: Over 1 — not on the tape: Return on Equity: Over +15%; Debt/Equity: Low (<0.1); P/E: Under 25
Value 0 of 4 — not on the tape: P/E: Under 15; P/B: Under 2; Return on Equity: Over +15%; Debt/Equity: Low (<0.1)
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 2 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 0 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200
Profile
EDVA52-week range, 0% of the way up
0.136.76
Endovia Health Sciences, Inc. engages in the sale and production of natural and healthy drinks. It offers products under the brands of Salt Tequila and Chispo Tequila. The company was founded on September 3, 1992 and is headquartered in Fort Lauderdale, FL.
| Employees | 2 |
|---|---|
| IPO | Feb 05, 2019 |
| Beta | -1.11 |
| ATR, 14d | 0.02 |
| Rel volume | 0.15 |
| Short float | 2.81% |
| Insider own | 0.01% |
| Inst own | 9.82% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | $1.91M |
| Enterprise Value | 8.06M |
| Income | -31.07M |
| Sales | 1.02M |
| Book / share | -3.82 |
| Cash / share | 0.02 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 2 |
| IPO | Feb 05, 2019 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 1.87 |
| Price / book | - |
| Price / cash | 7.94 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | 7.90 |
| Quick Ratio | 0.03 |
| Current Ratio | 0.03 |
| Debt / equity | - |
| Long-term debt / equity | - |
| Options and short | No / Yes |
Earnings
| Earnings / share | -68.97 |
|---|---|
| Earnings next year | - |
| Earnings next quarter | - |
| Earnings this year | - |
| Earnings next year | - |
| Earnings growth, 5 years | - |
| Past earnings growth | 19.99% 42.21% |
| Past sales growth | -84.07% -49.84% |
| Earnings vs last year | 65.38% |
| Sales vs last year | -83.63% |
| Earnings vs last quarter | 91.47% |
| Sales vs last quarter | -100.00% |
| Earnings | Aug 20 BMO |
| Surprise | 0.00% -53.24% |
Ownership
| Insiders own | 0.01% |
|---|---|
| Insider trades | 0.00% |
| Institutions own | 9.82% |
| Institution trades | 0.93% |
| Return on assets | -201.40% |
| Return on equity | - |
| Return on capital | - |
| Gross Margin | -191.86% |
| Operating margin | -1463.75% |
| Profit Margin | -3033.60% |
| 20-day average | 0.76% |
| 50-day average | -11.01% |
| 200-day average | -82.88% |
Technical
| Shares out | 11.41M |
|---|---|
| Shares floating | 11.41M |
| Short / float | 2.81% |
| Short ratio | 0.10 |
| Short interest | 0.32M |
| 52-week high | 6.76 -97.5% |
| 52-week low | 0.13 +24.6% |
| Volatility | 10.46% 9.01% |
| Average range | 0.02 |
| Strength index | 45.17 |
| Market sensitivity | -1.11 |
| Relative volume | 0.15 |
| Avg Volume | 3.34M |
| Volume | 481,699 |
Performance
| Perf Week | -1.12% |
|---|---|
| Perf Month | 19.20% |
| Perf Quarter | -58.77% |
| Perf Half Y | -82.38% |
| Perf YTD | -93.95% |
| Perf Year | -96.66% |
| Perf 3Y | -99.78% |
| Perf 5Y | -99.94% |
| Perf 10Y | - |
| Recommendation | 1.00 |
| Target Price | 160.00 |
| Prev Close | 0.17 |
| Price | 0.17 |
| Change % | -3.75% |
Peers
Mkt capHeld by
AUM| Ticker | Company | AUM |
|---|---|---|
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
News
latest 14 of 42- Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway (GlobeNewswire)
- Endovia Health Sciences Closes Initial Funding to Accelerate CannEpil Development Amid Growing Federal Support for Botanical Drug Pathways (GlobeNewswire)
- Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil FDA Submission and Expands Development Pipeline (GlobeNewswire)
- Endovia Health Sciences, formerly Splash Beverage, Achieves First FDA Regulatory Milestone for CannEpil Veterinary Development Program (GlobeNewswire) +8.48%
- Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker "EDVA" Effective Monday (GlobeNewswire) +10.94%
- Splash Beverage Reports Second Quarter 2026 Results and Highlights Strategic Transformation Toward Endovia Health Sciences (GlobeNewswire)
- Splash Beverage Group to Rebrand as Endovia Health Sciences (GlobeNewswire) +16.40%
- Splash Beverage Group Partners with Veteran Cannabinoid Drug-Development Team to Advance CannEpil Through FDA Veterinary Pathway (GlobeNewswire) +21.43%
- Splash Beverage Group Expands CannEpil Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program (GlobeNewswire) -9.33%
- Splash Beverage Group Announces Significant Balance Sheet Improvement and Board Approval of Reverse Stock Split as Company Continues Strategic Transformation (GlobeNewswire) -15.89%
- Splash Beverage Group Receives NYSE American Acceptance of Compliance Plan, Establishing Defined Path Toward Continued Listing and Strategic Transformation (GlobeNewswire)
- SBEV Stock Tumbles Over 35% In Pre-Market Today A Look At Its Latest Deal With Argent BioPharma (Stocktwits) -23.16%
- SPLASH BEVERAGE GROUP ACQUIRES EXCLUSIVE GLOBAL RIGHTS TO CANNEPIL, AN EPILEPSY THERAPY WITH ESTABLISHED EUROPEAN PATIENT ACCESS, FDA ENGAGEMENT AND U.S. DEVELOPMENT POTENTIAL (PR Newswire)
- Splash Beverage Group Acquires Exclusive Global Rights to CannEpil, an Epilepsy Therapy with Established European Patient Access, FDA Engagement and U.S. Development Potential (GlobeNewswire) +42.53%
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| 2024Q4 | 2025-02-26 | -0.320 | -0.320 | -25.181 | 1.80 | 1.80 | 1 |
| 2024Q3 | 2024-11-15 | -12.800 | -12.800 | -12.800 | 0.98 | 2.10 | 2 |
| 2024Q2 | 2024-08-14 | -0.440 | -0.360 | -17.352 | 1.05 | 1.60 | 2 |
| 2024Q1 | 2024-05-21 | -0.400 | -0.320 | -16.685 | 1.54 | 5.21 | 1 |
| 2023Q4 | 2024-03-29 | -0.360 | -0.400 | -21.976 | 2.69 | 6.00 | 1 |
| 2023Q3 | 2023-11-15 | -0.520 | -0.460 | -21.190 | 5.14 | 7.10 | 2 |
| 2023Q2 | 2023-08-14 | -0.520 | -0.440 | -21.342 | 5.20 | 6.79 | 2 |
| 2023Q1 | 2023-06-06 | -0.600 | -0.480 | -15.958 | 5.82 | 6.11 | 1 |
| 2022Q4 | 2023-03-31 | -0.520 | -0.560 | -18.667 | 4.79 | 4.90 | 1 |
| 2022Q3 | 2023-02-13 | -0.520 | - | -22.027 | 5.00 | - | - |
| 2022Q2 | 2022-08-15 | -0.640 | -0.200 | -25.123 | 4.50 | 6.00 | 1 |
| 2022Q1 | 2022-05-16 | -0.320 | -0.320 | -27.256 | 4.10 | 3.95 | 1 |
| 2021Q4 | 2022-04-22 | -0.760 | - | -29.034 | 2.78 | - | - |
| 2021Q3 | 2022-01-24 | -2.480 | - | -63.926 | 2.83 | - | - |
| 2021Q2 | 2021-08-18 | - | - | -38.371 | 3.29 | - | - |
| 2021Q1 | 2021-05-14 | - | - | -28.843 | 2.42 | - | - |
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2021FY | -4.080 | - | -160.83 | 11.32 | 11.80 |
| 2022FY | -92.800 | - | -93.454 | 18.09 | - |
| 2023FY | -79.200 | -77.600 | - | 18.90 | 22.05 |
| 2024FY | -1.400 | -1.400 | -70.998 | 5.37 | 5.37 |
| 2025FY | - | -1.240 | -47.864 | - | 13.49 |
| 2026FY | - | -1.320 | - | - | 17.89 |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| 2025Q1 | S | 2025-02-26 | 1 | 0 | 0 | 3.16 | 3.16 | 3.16 |
| 2025Q1 | S | 2025-02-09 | 1 | 0 | 0 | 3.16 | 3.16 | 3.16 |
| 2025Q1 | S | 2024-11-26 | 1 | 0 | 1 | 3.16 | 3.16 | 3.16 |
| 2025Q1 | S | 2024-11-15 | 1 | 0 | 0 | 9.50 | 9.50 | 9.50 |
| 2025Q1 | S | 2024-11-13 | 1 | 0 | 0 | 9.50 | 9.50 | 9.50 |
| 2025Q1 | S | 2024-08-30 | 1 | 1 | 0 | 9.50 | 9.50 | 9.50 |
| 2025Q1 | S | 2024-08-14 | 1 | 0 | 0 | 5.20 | 5.20 | 5.20 |
| 2025Q1 | S | 2024-06-24 | 1 | 0 | 0 | 5.20 | 5.20 | 5.20 |
| 2025Q1 | R | 2025-02-26 | 1 | 0 | 0 | -0.08 | -0.08 | -0.08 |
| 2025Q1 | R | 2025-02-09 | 1 | 0 | 0 | -0.08 | -0.08 | -0.08 |
| 2025Q1 | R | 2024-11-26 | 1 | 0 | 1 | -0.08 | -0.08 | -0.08 |
| 2025Q1 | R | 2024-11-15 | 1 | 0 | 0 | -0.06 | -0.06 | -0.06 |
| 2025Q1 | R | 2024-08-30 | 1 | 0 | 0 | -0.06 | -0.06 | -0.06 |
| 2025Q1 | E | 2025-02-26 | 1 | 0 | 0 | -0.08 | -0.08 | -0.08 |
Estimate history
| EPS, annual | -4.8 | 2.875 | -60.029 | -742.445 | -160.834 | -93.454 | -79.166 | -70.998 | -47.864 | -68.9684 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| EPS, quarterly | -16.685 | -17.352 | -143.213 | -25.181 | -7.862 | -17.881 | -18.044 | -2.2 | -0.67 | |
| Period | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | Q2 '26 | |
| Sales, annual | 0.895 | 1.309 | 0.02 | 2.3 | 11.316 | 18.087 | 18.85 | 0.801 | 0.073 | 1.02 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| Sales, quarterly | 1.541 | 1.047 | 0.982 | 0.586 | 0.438 | 0 | 0 | 0.004 | 0 | |
| Period | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | Q2 '26 | |
| Shares, annual | 0.023 | 0.024 | 0.091 | 0.044 | 0.21 | 0.257 | 0.277 | 0.417 | 0.75 | 4.127 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | MRQ |
| Shares, quarterly | 0.29 | 0.277 | 0.277 | 0.417 | 0.475 | 0.417 | 0.417 | 0.75 | 4.127 | |
| Period | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | Q2 '26 |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.07 | 0.80 | 18.85 | 18.09 | 11.32 | 2.30 | 0.02 | 1.31 |
| Cost of Goods Sold Incl. D&A | 0.01 | 11.73 | 6.19 | 19.45 | 23.76 | 18.11 | 9.86 | 1.32 | 0.99 |
| Gross Profit | -0.01 | -11.66 | -5.39 | -0.60 | -5.67 | -6.80 | -7.56 | -1.30 | 0.32 |
| Selling, General and Administrative Excl. Other | 2.00 | 2.53 | 0.19 | 14.68 | 15.72 | 22.28 | 10.10 | 3.18 | 0.25 |
| Other Operating Expense | 0.00 | 0.45 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.01 | -14.64 | -5.58 | -15.29 | -21.39 | -29.08 | -17.66 | -4.49 | 0.07 |
| Interest Expense | 0.24 | 4.37 | 7.38 | 5.69 | 0.25 | 0.44 | 1.98 | 0.67 | 0.01 |
| Unusual Expense | 0.00 | 5.58 | 4.65 | 0.00 | 0.00 | -0.18 | -0.04 | -0.02 | - |
| Net Income Before Taxes | -2.01 | -24.35 | -17.61 | -21.00 | -21.64 | -29.35 | -19.59 | -5.14 | 0.07 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -2.01 | -24.35 | -17.61 | -21.00 | -21.64 | -29.35 | -19.59 | -5.14 | 0.07 |
| Net Income From Continuing Operations | -2.01 | -24.35 | -17.61 | -21.00 | -21.64 | -29.35 | -19.59 | -5.14 | 0.07 |
| Net Income | -2.05 | -26.07 | -23.76 | -21.00 | -21.84 | -29.05 | -28.67 | -5.14 | 0.07 |
| EPS (Recurring) | -0.67 | -40.69 | -61.26 | -79.17 | -93.45 | -161.52 | -743.11 | -60.16 | 2.88 |
| EPS (Basic, Before Extraordinaries) | -0.67 | -47.86 | -71.00 | -79.17 | -93.45 | -160.83 | -742.44 | -60.03 | 2.88 |
| EPS (Diluted) | -0.67 | -47.86 | -71.00 | -79.17 | -93.45 | -160.83 | -742.44 | -60.03 | 2.88 |
| EBITDA | -2.00 | -14.18 | -5.43 | -14.74 | -20.45 | -28.85 | -17.52 | -4.41 | 0.13 |
| Non-Operating Income (Expense) | 0.24 | 0.23 | 0.00 | -0.03 | 0.01 | 0.00 | 0.02 | 0.00 | 0.01 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 1.11 | 8.62 | 2.36 | 1.17 | - | - | - | 0.16 | - |
| Price To Sales Ratio | - | 20.58 | 10.76 | 1.24 | 1.99 | 2.98 | 9.43 | 1,712.13 | - |
| Gross Margin | -191.86 | -15,954.12 | -672.56 | -3.21 | -31.35 | -60.08 | -328.77 | -6,395.46 | 24.49 |
| Operating Margin | -1,463.75 | -20,030.42 | -695.94 | -81.10 | -118.28 | -257.01 | -767.86 | -22,009.41 | 5.09 |
| Net Margin | -3,033.60 | -35,675.66 | -2,964.85 | -111.42 | -120.74 | -256.72 | -1,246.65 | -25,191.21 | 5.21 |
| Shares Outstanding | 4.13 | 0.75 | 0.42 | 0.28 | 0.26 | 0.21 | 0.04 | 0.09 | 0.02 |
| Market Capitalization | 1.98 | 1.98 | 10.75 | 23.70 | 38.12 | 39.24 | 74.26 | 10.04 | 8.01 |
Income statement, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 | 2024Q2 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.44 | 0.59 | 0.98 | 1.05 |
| Cost of Goods Sold Incl. D&A | 0.01 | 0.48 | 0.04 | 0.04 | 1.62 | 1.29 | 1.98 | 3.39 |
| Gross Profit | -0.01 | -0.47 | -0.04 | -0.04 | -1.18 | -0.71 | -1.00 | -2.34 |
| Selling, General and Administrative Excl. Other | 2.00 | 0.51 | 9.51 | 1.60 | 0.85 | 1.40 | 1.67 | 1.35 |
| Other Operating Expense | 0.00 | 0.03 | 0.00 | -0.33 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.01 | -1.01 | -9.54 | -1.30 | -2.03 | -2.11 | -2.67 | -3.69 |
| Interest Expense | 0.24 | 0.90 | 0.35 | 1.30 | 1.62 | 2.60 | 1.72 | 1.64 |
| Unusual Expense | 0.00 | 0.27 | 0.00 | 5.89 | 0.00 | 4.32 | 0.33 | 0.00 |
| Net Income Before Taxes | -2.01 | -2.14 | -9.89 | -8.49 | -3.65 | -9.04 | -4.72 | -5.33 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -2.01 | -2.14 | -9.89 | -8.49 | -3.65 | -9.04 | -4.72 | -5.33 |
| Net Income From Continuing Operations | -2.01 | -2.14 | -9.89 | -8.49 | -3.65 | -9.04 | -4.72 | -5.33 |
| Net Income | -2.05 | -2.51 | -9.89 | -8.49 | -3.65 | -9.04 | -4.72 | -5.33 |
| EPS (Recurring) | -0.67 | -2.03 | -18.04 | -9.20 | -7.86 | -16.75 | -136.20 | -17.35 |
| EPS (Basic, Before Extraordinaries) | -0.67 | -2.20 | -18.04 | -17.88 | -7.86 | -25.18 | -143.21 | -17.35 |
| EPS (Diluted) | -0.67 | -2.20 | -18.04 | -17.88 | -7.86 | -25.18 | -143.21 | -17.35 |
| EBITDA | -2.00 | -1.01 | -9.51 | -1.27 | -2.00 | -1.98 | -2.53 | -3.56 |
| Non-Operating Income (Expense) | 0.24 | 0.05 | 0.00 | 0.00 | -0.00 | -0.00 | 0.00 | 0.00 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 1.11 | 0.18 | 7.75 | 0.05 | 0.14 | 0.27 | 0.19 | 1.34 |
| Price To Sales Ratio | - | - | 5.05 | 3.56 | 0.85 | 2.23 | 0.21 | 1.08 |
| Gross Margin | - | -11,194.96 | - | - | -269.99 | -120.77 | -101.58 | -223.64 |
| Operating Margin | - | -23,888.45 | - | - | -463.76 | -360.37 | -271.89 | -352.60 |
| Net Margin | - | -59,482.60 | - | - | -832.92 | -1,542.85 | -480.68 | -508.86 |
| Shares Outstanding | 4.13 | 0.75 | 0.42 | 0.42 | 0.47 | 0.42 | 0.28 | 0.28 |
| Market Capitalization | 1.98 | 1.08 | 3.94 | 6.28 | 2.66 | 10.75 | 11.17 | 10.67 |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY | 2017FY |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 0.28 | 0.01 | 0.38 | 4.43 | 4.18 | 0.38 | 0.04 | 0.01 | 0.02 |
| Short Term Receivables | 0.11 | 0.43 | 1.12 | 2.16 | 1.16 | 0.58 | 0.02 | 0.30 | 0.15 |
| Inventories | 0.03 | 0.32 | 2.25 | 3.72 | 1.92 | 0.80 | 0.30 | 0.04 | 0.03 |
| Other Current Assets | 0.21 | 1.14 | 0.22 | 0.35 | 1.08 | 0.49 | 0.01 | - | - |
| Total Current Assets | 0.63 | 1.90 | 3.98 | 10.66 | 8.34 | 2.24 | 0.37 | 0.35 | 0.19 |
| Net Property, Plant & Equipment | 0.06 | 0.37 | 0.91 | 1.24 | 1.60 | 0.76 | 0.20 | 0.06 | 0.05 |
| Total Investments and Advances | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 4.72 | 5.11 | 5.86 | 5.89 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Assets | 37.90 | 33.70 | - | - | - | - | - | - | - |
| Other Assets | 0.02 | 0.23 | 0.05 | 0.05 | 0.33 | 0.08 | 0.03 | 0.00 | 0.00 |
| Total Assets | 38.86 | 36.46 | 9.90 | 17.30 | 16.39 | 9.23 | 0.61 | 0.41 | 0.24 |
| Short Term Debt Incl. Current Port. of LT Debt | 6.67 | 10.28 | 8.39 | 1.35 | 3.91 | 2.49 | 6.86 | 0.07 | 0.07 |
| Accounts Payable | 4.81 | 3.59 | 4.44 | 3.38 | 1.91 | 1.52 | 0.70 | 0.33 | 0.23 |
| Other Current Liabilities | 4.78 | 5.50 | 1.91 | 0.23 | 0.95 | 1.40 | 2.71 | -0.00 | -0.00 |
| Total Current Liabilities | 16.26 | 19.37 | 14.75 | 4.97 | 6.78 | 5.42 | 10.28 | 0.41 | 0.30 |
| Long Term Debt | 0.01 | 2.02 | 0.75 | 3.02 | 0.73 | 1.93 | 0.08 | 0.01 | 0.01 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 37.90 | 33.70 | - | - | - | - | - | - | - |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.98 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 54.16 | 55.09 | 15.50 | 7.98 | 7.51 | 9.33 | 10.36 | 0.41 | 0.31 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.25 | 0.00 | 0.00 | 0.00 |
| Common Equity | -15.30 | -18.63 | -5.61 | 9.32 | 8.87 | -9.35 | -9.76 | -0.00 | -0.07 |
| Total Shareholders Equity | -15.30 | -18.63 | -5.61 | 9.32 | 8.87 | -0.10 | -9.76 | -0.00 | -0.07 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | -15.30 | -18.63 | -5.61 | 9.32 | 8.87 | -0.10 | -9.76 | -0.00 | -0.07 |
| Total Liabilities & Stockholders Equity | 38.86 | 36.46 | 9.90 | 17.30 | 16.39 | 9.23 | 0.61 | 0.41 | 0.24 |
| Book Value Per Share | -20.41 | -44.64 | -20.23 | 36.30 | 42.26 | -212.14 | -106.71 | -0.11 | -3.10 |
| Tangible Book Value Per Share | -20.41 | -44.64 | -37.25 | 16.41 | 14.34 | -345.83 | -106.71 | -0.11 | -3.10 |
| Full-Time Employees | 2 | 21 | 32 | 40 | 21 | - | 9 | 9 | 9 |
| Price to Book Ratio | -0.05 | -0.58 | -36.03 | 3.81 | 4.42 | -7.94 | -45.83 | -67.89 | - |
| Return on Assets | -117.00 | -75.98 | -154.42 | -128.47 | -229.16 | -398.49 | -1,013.36 | 21.01 | -49.48 |
| Return on Equity | - | - | -1,130.20 | -237.86 | -669.13 | - | - | - | - |
| Return on Invested Capital | - | - | - | -176.99 | -302.43 | -1,566.72 | - | 2,402.47 | - |
| Quick Ratio | 0.04 | 0.08 | 0.12 | 1.40 | 0.95 | 0.27 | 0.01 | 0.76 | 0.56 |
| Current Ratio | 0.04 | 0.10 | 0.27 | 2.15 | 1.23 | 0.41 | 0.04 | 0.86 | 0.65 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -2.05 | -25.23 | -23.76 | -21.00 | -21.71 | -29.05 | -28.67 | -5.14 | 0.07 |
| Depreciation | -0.00 | 0.01 | 0.40 | 0.55 | 0.94 | 0.19 | 0.19 | 0.06 | 0.06 |
| Other Funds (Non Cash) | 1.19 | 17.43 | 11.69 | 5.00 | 7.37 | 15.95 | 8.01 | 1.98 | -0.01 |
| Funds from Operations | -0.86 | -7.79 | -11.67 | -15.45 | -13.40 | -12.91 | -20.47 | -3.09 | 0.12 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -0.23 | 3.00 | 3.87 | 5.26 | -0.69 | -2.22 | -0.91 | 0.43 | -0.06 |
| Cash from Operating Activities | -1.09 | -4.79 | -7.80 | -10.19 | -14.09 | -15.13 | -21.38 | -2.66 | 0.06 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | -0.01 | -0.10 | 0.00 | -0.09 | -0.01 | -0.08 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.25 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.25 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | -0.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.51 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.20 | 0.00 | 0.00 | -0.01 | -0.10 | 0.00 | -0.78 | -0.01 | -0.07 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 1.58 | 1.30 | 0.00 | 0.00 | 11.43 | 19.63 | 20.18 | 1.57 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 1.58 | 1.30 | 0.00 | 0.00 | 11.43 | 19.63 | 20.18 | 1.57 | 0.00 |
| Proceedsfrom Stock Options | 1.58 | 1.30 | 0.00 | 0.00 | 11.43 | 19.63 | 20.18 | 1.57 | 0.00 |
| Issuance or Reduction of Debt, Net | -0.42 | 3.80 | 7.54 | 5.57 | 3.41 | -0.75 | 2.44 | 0.10 | -0.01 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.01 | 0.58 | -0.39 | 0.13 | -0.05 | 0.15 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | -0.39 | -0.26 | -0.05 | 0.00 | 0.00 |
| Cash from Financing Activities | 1.16 | 5.10 | 7.54 | 6.15 | 14.45 | 18.93 | 22.49 | 1.78 | -0.01 |
| Exchange Rate Effect | 0.00 | -0.05 | 0.10 | 0.00 | - | - | - | - | - |
| Net Change in Cash | -0.14 | 0.27 | -0.15 | -4.05 | 0.25 | 3.80 | 0.34 | -0.90 | -0.01 |
| Free Cash Flow | - | -4.79 | -7.80 | -10.20 | -14.20 | -15.13 | -21.47 | -2.67 | -0.01 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 0.24 | 0.38 | 0.27 | 0.02 | 0.00 | 0.02 |
| Short Term Receivables | 0.09 | 0.10 | 0.35 | 0.36 | 0.39 | 0.63 |
| Inventories | 0.05 | 0.05 | 0.86 | 0.86 | 0.86 | 0.89 |
| Other Current Assets | 0.10 | 0.18 | 0.50 | 0.37 | 0.44 | 0.36 |
| Total Current Assets | 0.48 | 0.71 | 1.97 | 1.61 | 1.69 | 1.90 |
| Net Property, Plant & Equipment | 0.00 | 0.04 | 0.22 | 0.33 | 0.44 | 0.56 |
| Total Investments and Advances | 0.18 | 0.00 | 0.25 | 0.25 | 0.25 | 0.25 |
| Intangible Assets | 0.00 | 0.00 | 20.00 | 20.00 | 0.00 | 0.00 |
| Other Assets | 0.42 | 0.02 | 0.05 | 0.05 | 0.12 | 0.05 |
| Total Assets | 1.08 | 0.77 | 22.49 | 22.24 | 2.51 | 2.76 |
| Short Term Debt Incl. Current Port. of LT Debt | 6.39 | 6.35 | 6.34 | 4.17 | 10.29 | 10.53 |
| Accounts Payable | 4.09 | 4.63 | 6.75 | 7.04 | 6.32 | 5.23 |
| Other Current Liabilities | 6.35 | 5.99 | 2.55 | 2.23 | 3.81 | 3.61 |
| Total Current Liabilities | 16.83 | 16.97 | 15.64 | 13.45 | 20.42 | 19.37 |
| Long Term Debt | 0.00 | 0.00 | 0.07 | 0.07 | 2.12 | 2.02 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 16.83 | 16.97 | 15.71 | 13.52 | 22.54 | 21.39 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | -15.75 | -16.20 | 6.78 | 8.72 | -20.03 | -18.63 |
| Total Shareholders Equity | -15.75 | -16.20 | 6.78 | 8.72 | -20.03 | -18.63 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | -15.75 | -16.20 | 6.78 | 8.72 | -20.03 | -18.63 |
| Total Liabilities & Stockholders Equity | 1.08 | 0.77 | 22.49 | 22.24 | 2.51 | 2.76 |
| Book Value Per Share | -3.82 | -21.61 | 16.23 | 20.88 | -42.17 | -44.64 |
| Tangible Book Value Per Share | -3.82 | -21.61 | -31.67 | -27.03 | -42.17 | -44.64 |
| Full-Time Employees | - | - | - | - | - | 21 |
| Price to Book Ratio | -0.05 | -0.07 | 0.58 | 0.72 | -0.13 | -0.58 |
| Return on Assets | - | - | -201.40 | -171.00 | -410.87 | -375.36 |
| Return on Invested Capital | - | - | -144.38 | -96.61 | - | - |
| Quick Ratio | 0.03 | 0.04 | 0.07 | 0.06 | 0.04 | 0.05 |
| Current Ratio | 0.03 | 0.04 | 0.13 | 0.12 | 0.08 | 0.10 |
Cash flow, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 |
|---|---|---|---|---|---|---|
| Net Income | -2.05 | -2.14 | -9.89 | -8.49 | -3.65 | -9.04 |
| Depreciation | -0.00 | 0.00 | 0.04 | 0.04 | 0.04 | 0.13 |
| Other Funds (Non Cash) | 1.19 | 0.44 | 7.77 | 6.29 | 1.12 | 5.55 |
| Funds from Operations | -0.86 | -1.69 | -2.07 | -2.17 | -2.49 | -3.36 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -0.23 | 0.76 | -0.35 | 1.49 | 1.77 | 1.74 |
| Cash from Operating Activities | -1.09 | -0.93 | -2.42 | -0.68 | -0.72 | -1.62 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | -0.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | - | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 1.58 | 1.37 | 0.15 | 0.65 | 0.00 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 1.58 | 1.37 | 0.15 | 0.65 | 0.00 | 0.00 |
| Proceedsfrom Stock Options | 1.58 | 1.37 | 0.15 | 0.65 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | -0.42 | -0.32 | 2.53 | 0.05 | 0.76 | 1.16 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.15 |
| Cash from Financing Activities | 1.16 | 1.05 | 2.67 | 0.70 | 0.76 | 1.16 |
| Exchange Rate Effect | 0.00 | -0.02 | -0.00 | 0.00 | -0.05 | 0.02 |
| Net Change in Cash | -0.14 | 0.10 | 0.25 | 0.02 | -0.02 | -0.44 |
| Free Cash Flow | - | - | -2.42 | -0.68 | -0.72 | -1.62 |
Revenue breakdown
| Beverages | 2024: 801.27K 2025: 73.07K |
|---|---|
| United States | 2024: 801.27K 2025: 73.07K |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 2.81% | 0.3M | 11.4M | 4.04M |
| 2026-10-15 | 1.92% | 0.2M | 11.1M | 4.83M |
| 2026-09-30 | 1.57% | 0.2M | 11.1M | 6.82M |
| 2026-09-15 | 5.29% | 0.3M | 6.4M | 4.69M |
| 2026-08-31 | 3.56% | 0.2M | 6.4M | 9.12M |
| 2026-07-31 | 16.81% | 1.1M | 6.3M | 8.06M |
| 2026-07-15 | 2.29% | 0.1M | 6.3M | 6.46M |
| 2026-06-30 | 1.51% | 0.1M | 4.0M | 4.58M |
| 2026-06-15 | 1.08% | 0.0M | 3.8M | 4.54M |
| 2026-05-29 | 1.00% | 0.0M | 2.7M | 450.82K |
| 2026-05-15 | 2.00% | 0.1M | 2.7M | 555.20K |
| 2026-04-30 | 2.72% | 0.1M | 2.5M | 542.99K |
| 2026-04-15 | 6.39% | 0.1M | 2.3M | 517.76K |
| 2026-03-31 | 4.37% | 0.0M | 0.7M | 336.75K |
| 2026-03-13 | 3.93% | 0.0M | 0.7M | 247.48K |
| 2026-02-27 | 21.69% | 0.2M | 0.7M | 301.55K |
| 2026-02-13 | 5.25% | 0.0M | 0.7M | 387.61K |
| 2026-01-30 | 5.54% | 0.0M | 0.7M | 378.29K |
| 2026-01-15 | 0.32% | 0.0M | 0.6M | 530.32K |
| 2025-12-31 | 0.63% | 0.0M | 0.6M | 521.75K |
Option chain
expiry 2026-11-12| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-04 | 424B3 | SEC | ||
| 2026-11-03 | EFFECT | Effectiveness filing by commission order | SEC | |
| 2026-11-02 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-11-02 | SEC |
| 2026-10-27 | S-1 | General form of registration statement for all companies including face-amount certificate companies | SEC | |
| 2026-10-27 | 8-K | Current report | 2026-10-22 | SEC |
| 2026-10-23 | PRE 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-10-23 | SEC |
| 2026-10-22 | SCHEDULE 13G | SEC | ||
| 2026-10-15 | 8-K | Current report | 2026-10-15 | SEC |
| 2026-10-08 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-10-06 | 8-K | Current report | 2026-09-30 | SEC |
| 2026-10-05 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-10-05 | SEC |
| 2026-10-05 | 8-K | Current report | 2026-10-05 | SEC |
| 2026-09-24 | 8-K | Current report | 2026-09-18 | SEC |
| 2026-09-23 | PRE 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-09-23 | SEC |
| 2026-09-22 | 8-K | Current report | 2026-09-22 | SEC |
| 2026-09-18 | PRE 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-09-18 | SEC |
| 2026-08-31 | 8-K | Current report | 2026-08-31 | SEC |
| 2026-08-28 | 8-K | Current report | 2026-08-25 | SEC |
| 2026-08-28 | 424B3 | SEC | ||
| 2026-08-26 | 8-K | Current report | 2026-08-20 | SEC |
| 2026-08-25 | 8-K | Current report | 2026-08-24 | SEC |
| 2026-08-24 | EFFECT | Effectiveness filing by commission order | SEC | |
| 2026-08-21 | 8-K | Current report | 2026-08-21 | SEC |
| 2026-08-20 | S-1/A | SEC | ||
| 2026-08-20 | 8-K | Current report | 2026-08-20 | SEC |
| 2026-08-19 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-17 | NT 10-Q | 2026-06-30 | SEC | |
| 2026-08-12 | 8-K | Current report | 2026-08-12 | SEC |
| 2026-08-11 | 8-K | Current report | 2026-08-05 | SEC |
| 2026-08-07 | S-1 | General form of registration statement for all companies including face-amount certificate companies | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| JANE STREET GROUP, LLC | 8.44% |
| Summit Trail Advisors, LLC | 2.42% |
| TRUIST FINANCIAL CORP | 1.64% |
| Virtu Financial LLC | 1.45% |
| Point72 Asset Management, L.P. | 1.38% |
| HRT FINANCIAL LP | 1.37% |
| Phraction Management LLC | 0.78% |
| GOLDMAN SACHS GROUP INC | 0.49% |
| StoneX Group Inc. | 0.43% |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.26% |
Funds
| Fund | % owned |
|---|---|
| - | |
OakChart. EDVA. Cached 15 minutes. Terms
Some panels did not load: ratings, insider.